VPS35 Antibody (1114723) [Unconjugated]

VCTS021). Tissue was stained using the HRP-conjugated Anti-Mouse IgG Secondary Antibody (HAF007) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm and membrane in breast tumor. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections." > VCTS021). Tissue was stained using the HRP-conjugated Anti-Mouse IgG Secondary Antibody (HAF007) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm and membrane in breast tumor. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections." title="VSP35 was detected in immersion fixed paraffin-embedded sections of human breast tumor using Mouse Anti-Human VSP35 Monoclonal Antibody (Catalog # MAB11770) at 5 µg/ml overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (VCTS021). Tissue was stained using the HRP-conjugated Anti-Mouse IgG Secondary Antibody (HAF007) and counterstained with hematoxylin (blue). Specific staining was localized to the cytoplasm and membrane in breast tumor. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections." />

VSP35 was detected in immersion fixed paraffin-embedded sections of human breast tumor using Mouse Anti-Human VSP35 Monoclonal Antibody (Catalog # MAB11770) at 5 µg/ml overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (<a class=

• Reactivity: Hu
• Clone: 1114723
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

VPS35 Antibody (1114723) [Unconjugated] Summary

• Immunogen: Synthetic Peptide
  Accession # Q96QK1
• Specificity: Detects a synthetic peptide specific for human VPS35 around amino acid 790 in Direct ELISA.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Reconstitution Instructions: Reconstitute lyophilized material at 0.2 mg/ml in sterile PBS. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for VPS35 Antibody (1114723) [Unconjugated]

• DKFZp434P1672
• FLJ10752
• FLJ13588
• FLJ20388
• hVPS35
• Maternal-embryonic 3
• MEM3
• MEM3DKFZp434E1211
• PARK17
• vacuolar protein sorting 35 (yeast homolog)
• vacuolar protein sorting 35 (yeast)
• vacuolar protein sorting 35 homolog (S. cerevisiae)
• vacuolar protein sorting-associated protein 35
• Vesicle protein sorting 35
• VPS35

Background

VPS35 (vacuolar protein sorting-associated protein 35) is a critical component of the retromer complex, which plays an essential role in intracellular trafficking and protein recycling. With a molecular weight of approximately 90 kDa, VPS35 is responsible for mediating the retrieval of proteins and receptors from endosomes to their target destinations, including the trans-Golgi network and the plasma membrane. This process is crucial for maintaining cellular homeostasis, membrane integrity, and signaling pathways. VPS35 is ubiquitously expressed in various tissues and is fundamental for normal cellular function, particularly neuronal health. Dysregulation or mutation of VPS35 has been strongly linked to neurodegenerative diseases, such as Parkinson's disease, due to its role in recycling transmembrane proteins that regulate synaptic and neuronal stability. Furthermore, emerging evidence suggests VPS35 involvement in cellular mechanisms related to autophagy, mitochondrial function, and inflammation. VPS35 appears to play a role in maintaining lysosome and mitochondria integrity, processes that are often disrupted in cancer cells to support their metabolic and invasive properties. Emerging evidence suggests that VPS35 dysregulation could also contribute to chemo-resistance in malignancies, including breast cancer. Because of its role in endosomal trafficking, neuronal health, and cancer biology, VPS35 represents a promising biomarker and therapeutic target for neurodegenerative disorders and oncological diseases.

1. Burd, C. et al. (2014) Cold Sprin Harb Perspect Biol. 6(2):a016774.
2. Fan, X. et al. (2025) J. Inflamm. Res. 18:4665-4680.
3. Li, X. et al. (2021) Cancer Cell Int. 21(1):265.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.